Quest Diagnostics (DGX) shares jumped after Q2 results beat Wall Street expectations and the company raised its full-year 2026 guidance. The upside relative to consensus and improved outlook point to stronger-than-expected operating momentum, supporting positive near-term sentiment for the stock.
Quest Diagnostics (DGX) shares jumped after Q2 results beat Wall Street expectations and the company raised its full-year 2026 guidance. The upside relative to consensus and improved outlook point to stronger-than-expected operating momentum, supporting positive near-term sentiment for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
